A view on drug resistance in cancer

N Vasan, J Baselga, DM Hyman - Nature, 2019 - nature.com
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Liquid biopsies come of age: towards implementation of circulating tumour DNA

JCM Wan, C Massie, J Garcia-Corbacho… - Nature Reviews …, 2017 - nature.com
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

J Tie, Y Wang, C Tomasetti, L Li, S Springer… - Science translational …, 2016 - science.org
Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may
identify patients at the highest risk of recurrence and help inform adjuvant treatment …

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

[HTML][HTML] The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded

RJ Kurman, IM Shih - The American journal of pathology, 2016 - Elsevier
Since our proposal of a dualistic model of epithelial ovarian carcinogenesis more than a
decade ago, a large number of molecular and histopathologic studies were published that …

High grade serous ovarian carcinomas originate in the fallopian tube

SI Labidi-Galy, E Papp, D Hallberg, N Niknafs… - Nature …, 2017 - nature.com
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer
and has a poor outcome. It has been proposed that fallopian tube cancers may be …

Tumour heterogeneity in the clinic

PL Bedard, AR Hansen, MJ Ratain, LL Siu - Nature, 2013 - nature.com
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management

AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

[HTML][HTML] The next-generation sequencing revolution and its impact on genomics

DC Koboldt, KM Steinberg, DE Larson, RK Wilson… - Cell, 2013 - cell.com
Genomics is a relatively new scientific discipline, having DNA sequencing as its core
technology. As technology has improved the cost and scale of genome characterization over …

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

JD Cohen, AA Javed, C Thoburn… - Proceedings of the …, 2017 - National Acad Sciences
The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future.
Here we describe our efforts to develop a noninvasive blood test for the detection of …